Logo_Horizontal_Fill_White_Transparent.png
Neurona Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Lifesciences Conference
February 07, 2024 16:01 ET | Neurona Therapeutics
Neurona Therapuetics presentation at upcoming Oppenheimer 34th Annual Healthcare Lifesciences Conference
Logo_Horizontal_Fill_White_Transparent.png
Neurona Therapeutics Presents New Clinical Data from First Cohort in Ongoing Phase I/II Open-Label Trial of NRTX-1001 Cell Therapy for Drug-resistant Mesial Temporal Lobe Epilepsy (MTLE)
December 01, 2023 09:00 ET | Neurona Therapeutics
Neurona Therapeutics presents new positive clinical data from 1st cohort in Ph I/II Trial of NRTX-1001 for drug reistant focal epilepsy at AES meeting
Logo_Horizontal_Fill_White_Transparent.png
Neurona Therapeutics Completes Clinical Enrollment of First Cohort and Updates on Long-lasting Impact in First Patients Treated in Ongoing Phase I/II Trial of NRTX-1001 Cell Therapy for Drug-resistant Focal Epilepsy
October 19, 2023 08:00 ET | Neurona Therapeutics
First cohort treated in Ph I/II clinical trial of NRTX-1001 in adults with focal epilepsy, update on first patients'progress
Logo_Horizontal_Fill_White_Transparent.png
Neurona Therapeutics Announces Participation in Upcoming Investor Conferences in October
October 10, 2023 16:01 ET | Neurona Therapeutics
Neurona Therapeutics CEO to participate in October Investor Conferences
Logo_Horizontal_Fill_White_Transparent.png
Neurona Therapeutics Announces Publication in Cell Stem Cell Reporting the Development of Investigational Novel Regenerative Cell Therapy Strategy for Drug-resistant Focal Epilepsy
October 05, 2023 11:00 ET | Neurona Therapeutics
Publication of preclinical studies supporting ongoing open-label first-in-human Phase I/II trial of cell therapy for drug-resistant focal epilepsy
Logo_Horizontal_Fill_White_Transparent.png
Neurona Therapeutics Appoints James Stutz as Chief Financial Officer and Chief Business Officer
July 31, 2023 08:00 ET | Neurona Therapeutics
SAN FRANCISCO, July 31, 2023 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurological...
Logo_Horizontal_Fill_White_Transparent.png
Neurona Therapeutics Presents One-Year Data on the First Patient Treated with NRTX-1001 Cell Therapy in an Ongoing Phase I/II Trial for Drug-resistant Focal Epilepsy
June 15, 2023 11:05 ET | Neurona Therapeutics
Promising reduction (>95%) in seizure frequency at the key one-year post treatment endpoint in the first patient to receive NRTX-1001, memory improvements, and seizure-freedom since seven-months...
Logo_Horizontal_Fill_White_Transparent.png
Neurona Therapeutics Presents Updated Data from the NRTX-1001 Cell Therapy Trial in Adults with Drug-resistant Focal Epilepsy at American Academy of Neurology (AAN) 2023 Annual Meeting
April 24, 2023 08:00 ET | Neurona Therapeutics
NRTX-1001 administration is well-tolerated with continued seizure reduction of >90% in the first two patients at nine- and five-months post-treatment, respectively Impaired-awareness seizures...
Logo_Horizontal_Fill_White_Transparent.png
Neurona Therapeutics Announces Presentation at the Oppenheimer 33rd Annual Healthcare Conference
March 08, 2023 16:01 ET | Neurona Therapeutics
SAN FRANCISCO, March 08, 2023 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for the treatment of neurological disorders,...
Logo_Horizontal_Fill_White_Transparent.png
Neurona Therapeutics Announces FDA Clearance of Expanded Inclusion Criteria for Phase I/II Clinical Trial of NRTX-1001 Regenerative Cell Therapy in Patients with Dominant Hemisphere Drug-Resistant Focal Epilepsy
February 14, 2023 08:00 ET | Neurona Therapeutics
NRTX-1001 administration is well-tolerated and shows seizure reduction of >90% in the first two patients at six- and three-months post-treatment, respectively Data & Safety Monitoring Board...